Pfizer(PFE)
NEW YORK, NY
Pharmaceutical2 H-1B visas (FY2023)Focus: Solid Oral Dosage Forms
Pfizer is a life sciences company focused on Solid Oral Dosage Forms.
OncologyImmunologyRare DiseasesVaccinesInternal Medicine
Funding Stage
PUBLIC
Employees
88,000
Open Jobs
614
Products & Portfolio (11)
39 discontinued products not shown
ABRILADA
adalimumab-afzb
Peak
mAbINJECTION · INJECTABLE
TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques. In Ps, treatment with ABRILADA may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which adalimumab products exert their clinical effects is unknown. Adalimumab products also modulate biological responses that are induced or regulated by TNF, including changes in the concentrations of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1–2 × 10M).
moderately to severely active Crohn's disease in adultsoldermoderately to severely active ulcerative colitis in adult patients+10 more
2019
30
ACETYLCYSTEINE
acetylcysteine
Post-LOE
INHALATION, ORAL · SOLUTION
Reduction Activity
asthma
1994
30
ACETYLCYSTEINE
acetylcysteine
Post-LOE
INHALATION, ORAL · SOLUTION
Reduction Activity
asthma
1994
30
ADCETRIS
brentuximab vedotin
Peak
ADCINJECTION · INJECTABLE
CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of sALCL cells and on Hodgkin Reed-Sternberg (HRS) cells in cHL. CD30 is variably expressed in other T-cell lymphomas. Expression of CD30 on healthy tissue and cells is limited. In vitro data suggest that signaling through CD30-CD30L binding may affect cell survival and proliferation. Brentuximab vedotin is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against CD30. The small molecule, MMAE, is a microtubule-disrupting agent. MMAE is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of ADCETRIS is due to the binding of the ADC to CD30-expressing cells, followed by internalization of the ADC‑CD30 complex, and the release of MMAE via proteolytic cleavage. Binding of MMAE to tubulin disrupts the microtubule network within the cell, subsequently inducing cell cycle arrest and apoptotic death of the cells. Additionally, in vitro data provide evidence for antibody-dependent cellular phagocytosis (ADCP).
IV cHLcombination with doxorubicinvinblastine+22 more
2011
30
ADCETRIS
brentuximab vedotin
Peak
ADCINJECTION · INJECTABLE
CD30-directed Antibody Interactions
IV cHLcombination with doxorubicinvinblastine+22 more
2011
30
ADRENALIN
epinephrine
Peak
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · SOLUTION
Adrenergic alpha-Agonists
2012
0
ADRENALIN
epinephrine
Peak
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · SOLUTION
Adrenergic alpha-Agonists
2013
0
ADRENALIN
epinephrine in sodium chloride
Growth
INTRAVENOUS · SOLUTION
Adrenergic alpha-Agonists
2023
0
ALDACTONE
spironolactone
LOE Approaching
ORAL · TABLET
Aldosterone Antagonists
NYHA Class III–IV heart failurereduced ejection fraction to increase survivalmanage edema+16 more
1960
30
ALISKIREN HEMIFUMARATE
aliskiren
Post-LOE
ORAL · TABLET
perfusion. Renin cleaves angiotensinogen to form the inactive decapeptide angiotensin I (Ang I). Ang I is converted to the active octapeptide angiotensin II (Ang II) by ACE and non-ACE pathways. Ang II is a powerful vasoconstrictor and leads to the release of catecholamines from the adrenal medulla and prejunctional nerve endings. It also promotes aldosterone secretion and sodium reabsorption. Together, these effects increase blood pressure. Ang II also inhibits renin release, thus providing a negative feedback to the system. This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS). Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known. All agents that inhibit the RAAS, including renin inhibitors, suppress the negative feedback loop, leading to a compensatory rise in plasma renin concentration. When this rise occurs during treatment with ACEIs and ARBs, the result is increased levels of PRA. During treatment with aliskiren, however, the effect of increased renin levels is blocked so that PRA, Ang I and Ang II are all reduced, whether aliskiren is used as monotherapy or in combination with other antihypertensive agents.
hypertension in adultsgreaterto lower blood pressure+3 more
2019
30
ALLOPURINOL
allopurinol
Post-LOE
ORAL · TABLET
Xanthine Oxidase Inhibitors
leukemialymphoma
2003
30
Pipeline & Clinical Trials
Tofacitinib
Arthritis RheumatoidClinical Trials (5)
NCT02092467Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Phase 4NCT06112665ToFAcitinib in Early Active Axial SpondyloarThritis:
Phase 4NCT02187055An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
Phase 4+2 more
Arm 1: E-portal message with IVR call
InfluenzaClinical Trials (1)
NCT02266277System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts
N/AReal-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Uti
Metastatic Breast CancerClinical Trials (1)
NCT02315365Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer
N/Asurveillance
Invasive Meningococcal DiseaseClinical Trials (5)
NCT04184336Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada
N/ANCT05754710Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
N/ANCT04889495A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
N/A+2 more
No intervention
Alzheimer DiseaseClinical Trials (5)
NCT03823794Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
N/ANCT01856569Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
N/ANCT05198245Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
N/A+2 more
ERB-041
Cystitis, InterstitialClinical Trials (5)
NCT00110487Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women
Phase 2NCT00434187Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects
Phase 1NCT00245947Study Evaluating ERB-041 in Active Crohn's Disease
Phase 1+2 more
Aromasin
Breast NeoplasmsClinical Trials (5)
NCT01176916Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
Phase 4NCT01237327Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
Phase 3NCT00036270Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Phase 3+2 more
Treadmill testing
Heart RateClinical Trials (1)
NCT00143988Heart Rate and Blood Pressure Response During Exercise and Sexual Activity in Normotensive and Hypertensive Volunteers
N/ATNF blockers monotherapy
Rheumatoid ArthritisClinical Trials (1)
NCT02927535Evaluation of TNFα Blockers Monotherapy in Early Rheumatoid Arthritis in France
N/Asunitinib
Pancreatic Neuroendocrine TumorsClinical Trials (5)
NCT00793871Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
Phase 4NCT00706706Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
Phase 4NCT03013946Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
Phase 3+2 more
Minimal Intervention
Cardiovascular Risk Reduction of Having a Coronary EventClinical Trials (1)
NCT01620996A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR)
N/ANewSpringForMe digital solution
Hematologic DiseasesENBREL®
Rheumatoid ArthritisAvelumab
Urothelial CarcinomaClinical Trials (5)
NCT03642132Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
Phase 3NCT02603432A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Phase 3NCT05059522Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Phase 3+2 more
Enhanced Clinical Intervention
Bipolar DisorderDesvenlafaxine
Major Depressive DisorderClinical Trials (5)
NCT02200406Desvenlafaxine in Opioid-Dependent Patients
Phase 4NCT00952653Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
Phase 4NCT01492621Effect of Antidepressants on White Matter Structure
Phase 4+2 more
Tofacitinib
Blau SyndromeClinical Trials (1)
NCT06688838Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome
N/ASmoking cessation
Smoking CessationClinical Trials (5)
NCT00596882Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study
Phase 4NCT00889720A Pilot Study Of Smoking Cessation Treatment Including Varenicline In Patients Scheduled For Planned Surgery
Phase 4NCT00818207Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit
Phase 4+2 more
Pregabalin
NeuralgiaClinical Trials (5)
NCT01603394Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
Phase 4NCT01226667Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia
Phase 4NCT00407511Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Phase 4+2 more
No Patient Counseling
Medication Non-AdherenceClinical Trials (1)
NCT01078285Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor
N/ARheumatoid Arthritis Satisfaction Outcome Research
Rheumatoid ArthritisClinical Trials (1)
NCT03703817Rheumatoid Arthritis Satisfaction Outcome Research
N/Aconsultation 10 days later
DepressionClinical Trials (1)
NCT01707576Screening of Adolescent Mental Suffering
N/AInlyta
Renal Cell CarcinomaClinical Trials (1)
NCT04555603Axitinib Therapy Management Study
N/AHanyang University Medical Center Arthritis Network
Arthritis, RheumatoidClinical Trials (1)
NCT00418405Hanyang University Medical Center Arthritis Network
N/APalbociclib + endocrine therapy
Breast NeoplasmsClinical Trials (1)
NCT04767594First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
N/ASomatropin and pegvisomant
MetabolismClinical Trials (1)
NCT00476879Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content
N/ABiochemical and Radiological Indicators of Cardiovascular Morbidity in Children With Premature Pubar
Evidence of Cardiovascular MorbidityClinical Trials (1)
NCT00581490Biochemical and Radiological Indicators of Cardiovascular Morbidity in Children With Premature Pubarche
N/ATigecycline
Intra-Abdominal InfectionsClinical Trials (5)
NCT01721408A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
Phase 4NCT01560143Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects
Phase 4NCT00230971Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
Phase 4+2 more
Triadic parent-infant Relationship Therapy
Preterm BirthClinical Trials (1)
NCT02394444Impact of an Intervention Program on Parenting Stress After Preterm Birth
N/AHIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vander
HIVClinical Trials (1)
NCT01339416HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University
N/APersistent SARS-CoV-2 Infection in Children With Cancer and Impaired Immune Responsiveness
Children With CancerClinical Trials (1)
NCT05172063Persistent SARS-CoV-2 Infection in Children With Cancer and Impaired Immune Responsiveness
N/AFocus Group
Breast CancerClinical Trials (1)
NCT04504201Patient-centered Communication About Healthy Weight in Early Breast Cancer
N/AAtorvastatin
HyperlipidemiaClinical Trials (1)
NCT00172419The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients.
N/Aetanercept
Rheumatoid ArthritisClinical Trials (1)
NCT00195338Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg
N/Avarenicline
Smoking CessationClinical Trials (5)
NCT00948155Measuring Smoking Behaviors While Using Varenicline
Phase 4NCT01836276Understanding Disparities in Quitting in African American and White Smokers
Phase 4NCT00749658Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence
Phase 2/3+2 more
Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)
Cardiac AmyloidosisClinical Trials (1)
NCT06921408Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)
N/ARetrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The
Non-small Cell Lung CancerClinical Trials (1)
NCT02304406Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
N/ABretovameran
COVID-19 VaccinationClinical Trials (1)
NCT06613984Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)
N/APrimary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine
COVID-19Clinical Trials (1)
NCT04848584Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California
N/AAromasin
Invasive Early Breast CancerClinical Trials (1)
NCT01121549A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
N/AOpen Label Treatment Access: Maraviroc
Human Immunodeficiency Virus (HIV)Clinical Trials (1)
NCT00992654A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
N/Amaraviroc
HIVClinical Trials (1)
NCT01329783EuroSIDA As An External Comparator To MOTIVATE Trials
N/AStudy Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
Ankylosing SpondylitisClinical Trials (1)
NCT00227227Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
N/APalbociclib + an aromatase inhibitor
Metastatic Breast CancerClinical Trials (1)
NCT04176354Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy
N/Asmoking questionnaire
Plaque PsoriasisClinical Trials (1)
NCT02192164Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis
N/ARefacto AF
Hemophilia AClinical Trials (5)
NCT00037544Study Evaluating ReFacto AF in Severe Hemophilia A
Phase 3NCT00243659Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
Phase 3NCT00038935Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A
Phase 3+2 more
Non intervention
Product Surveillance, PostmarketingClinical Trials (5)
NCT00836745Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent
N/ANCT01947894A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients
N/ANCT00858143Non Interventional Study For Patients Treated With Somavert®
N/A+2 more
Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by A
Atrial FibrillationClinical Trials (1)
NCT05116267Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by Apixaban in Belgium
N/AVoriconazole
Scedosporium InfectionClinical Trials (1)
NCT01660334Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan)
N/Apegaptanib sodium
Macular DegenerationClinical Trials (5)
NCT00324116Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
Phase 4NCT01175070Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
Phase 4NCT01486771Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)
Phase 4+2 more
Open Jobs (614)
Senior Oncology Account Specialist Hematology Detroit, MI
Remote
Manufacturing23h ago
$109K - $251K/yr
VP, Head of Oncology Biometrics
United States - Washington – Bothell
Data Science & AI23h ago
$274K - $457K/yr
Neuroscience Health and Science Professional - Springfield, MA
United States - Massachusetts - Springfield
Manufacturing23h ago
$72K - $187K/yr
Global Commercial Lead, Fetrastobart Vedotin
United States - New York - New York City
Commercial23h ago
$215K - $358K/yr
高级医学信息沟通专员
China - Shandong - Qingdao
23h ago
[MA] Lung Cancer MAS team, ONC Field MAS [Manager/Staff]
Japan - Tokyo
23h ago
[JDSU] 医薬品安全性統括部 ケースマネジメントチーム(一般社員) (Staff, Case Management, Japan Drug Safety Unit)
Japan - Tokyo
Pharmacovigilance23h ago
Manager, Digital and Technology, Controllers Delivery
United States - New York - New York City
23h ago
$99K - $165K/yr
Senior Associate Scientist
United States - Massachusetts - Andover
Research & Development23h ago
$69K - $114K/yr
Healthcare Access Manager
Saudi Arabia - Jeddah
Commercial23h ago
Product Owner
Belgium - Puurs
23h ago
Senior Health Representative (Oncology - North region)
Viet Nam - Hanoi
23h ago
Material Handler - 8 Hour Day Shift
United States - Kansas - McPherson
Manufacturing23h ago
Senior Associate Scientist- Formulations
United States - Massachusetts - Andover
Research & Development23h ago
$69K - $114K/yr
Senior Process Technician - Rotating 2nd Shift
United States - Massachusetts - Andover
Manufacturing23h ago
$27 - $45/hr
Field Medical Manager, Oncology
Malaysia - Kuala Lumpur
Business Development23h ago
National Account Manager Jr - Mendoza
Argentina - Buenos Aires
Commercial23h ago
Trainee Supervisor
India - Vizag
Manufacturing23h ago
Team Leader
India - Vizag
Manufacturing23h ago
辉瑞制药-高级医学信息沟通专员-偏头痛-天津
China - Tianjin - Tianjin
IT23h ago
高级医学信息沟通专员
China - Shandong - Qingdao
23h ago
医学信息沟通专员
China - Guangdong - Guangzhou
23h ago
高级客户解决方案专员
China - Beijing - Beijing
23h ago
Customs and Compliance Operations Manager
Viet Nam - Ho Chi Minh
Legal & IP23h ago
Senior Manager, HTA, Value and Evidence (HV&E), Medical Dermatology
United States - New York - New York City
23h ago
$139K - $232K/yr
Interview Prep Quick Facts
Portfolio: 1472 approved products, 204 clinical trials
Top TAs: Oncology, Neurology, Infectious Diseases
H-1B (2023): 2 approvals
Publications: 25 in PubMed
SEC Filings: 2 available
Open Roles: 614 active jobs
Portfolio Health
Pre-Launch231 (16%)
Growth10 (1%)
Peak58 (4%)
LOE Approaching510 (35%)
Post-LOE663 (45%)
1472 total products
Therapeutic Area Focus
Oncology
81 marketed1265 pipeline
Neurology
96 marketed393 pipeline
Infectious Diseases
50 marketed337 pipeline
Immunology
46 marketed320 pipeline
Cardiovascular
73 marketed229 pipeline
Metabolic Diseases
10 marketed228 pipeline
Respiratory
38 marketed99 pipeline
Nephrology
13 marketed104 pipeline
Marketed
Pipeline
Financials (FY2025)
Revenue
$59.6B41%
R&D Spend
$10.7B(18%)7%
Net Income
$2.1BCash
$1.0BHiring Trend
Actively Hiring
614
Open Roles
+667
Added
-53
Filled/Removed
Based on last 3 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub